FOXG1 Research Foundation

What FOXG1 Research Foundation does

FOXG1 Research Foundation is a parent-led, U.S.-based 501(c)(3) nonprofit founded in 2017 to develop treatments and ultimately a cure for FOXG1 syndrome, a rare neurodevelopmental disorder caused by mostly de-novo FOXG1 mutations affecting approximately 2,000 known patients worldwide. The foundation directly funds and de-risks a multi-modality therapeutic pipeline — anchored by FRF-001, an AAV9 viral vector gene replacement therapy that the FDA has cleared for patient clinical trials beginning in 2026 — alongside preclinical programs in antisense oligonucleotides (ASO), RNA interference (RNAi), suppressor tRNA, CRISPRa gene activation, and small-molecule drug repurposing. Multiple FDA designations (Orphan Drug, Rare Pediatric Disease, Fast Track) and the first FOXG1-specific ICD-10 diagnosis code (QA00.151, effective Oct 1, 2025) reinforce the lead program's regulatory position.

The foundation's revenue model is donations- and grant-based rather than commercial: it runs the $22M 'Yes, They Can!' campaign (~$14.5M raised to date, $4.5M in 2025 alone), supplemented by grants from pharmaceutical partners, family foundations, and rare-disease organizations, with peer-to-peer fundraising (e.g., Tom Horton's $1.2M El Camino walk) and corporate sponsorships (Blockchain.com, Consello, Fondation THOT, TAFF) as supplementary inflows. Its go-to-market is community-led: a 50+ country network of patient families, six formal affiliate chapters (Australia, France, Italy, Spain, Japan, Mexico), and 11+ U.S. Clinical Centers of Excellence (Texas Children's, Boston Children's, NYU Langone, CHOP, Stanford, UCSF, etc.) provide patient access, site readiness, and trial recruitment infrastructure.

Underlying the development pipeline is an integrated patient-data platform that combines a global FOXG1 Patient Registry, an AI-powered Citizen Health Digital Natural History Study, a stem cell biobank housed with the Coriell Institute, and a postmortem brain tissue program via Autism BrainNet — together representing one of the most complete rare-disease translational data stacks relative to the indication's ~2,000-patient population. Key research collaborators include the FOXG1 Research Center at the University at Buffalo (Lee Lab), SISSA's Mallamaci Lab, the Ahern Lab (Iowa), the Bedwell Lab (UAB), and the Fink Lab (UC Davis), with IQVIA Biotech engaged as clinical trial vendor for FRF-001.

Name

FOXG1 Research Foundation

Legal name

FOXG1 Research Foundation

Website

https://foxg1research.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

FOXG1 Research Foundation is a parent-led 501(c)(3) nonprofit founded in 2017 that develops treatments for FOXG1 syndrome, an ultra-rare neurodevelopmental disorder affecting ~2,000 patients worldwide. It funds a multi-modality pipeline led by FDA-cleared AAV9 gene replacement therapy, supported by a global patient registry, AI-powered natural history study, and stem cell biobank.

Ownership category

akta.pro rank

Product category

Rare Disease Patient Advocacy and Gene Therapy Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Rare disease research
• Gene therapy development
• Patient advocacy services
• Clinical trial funding
• Natural history studies

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Donations and Fundraising: The foundation raises funds through individual donations, peer-to-peer fundraising campaigns, major donor cultivation, corporate sponsorships, and special events. The primary 'Yes, They Can!' campaign aims to raise $22 million to fund gene therapy clinical trials. Individual fundraising events include walks, community fundraisers, school-based initiatives, and restaurant partnership programs.
2. Grants: Foundation receives grants from pharmaceutical companies, family foundations, and rare disease organizations to support research programs, clinical trial preparation, and operational activities.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

The FOXG1 Research Foundation is a parent-led nonprofit that funds and drives therapeutic research programs for FOXG1 syndrome, a rare neurodevelopmental disorder. Its core offerings include the FRF-001 AAV9 gene replacement therapy entering clinical trials in 2026, a pipeline of additional modality programs (ASO, RNAi, tRNA, CRISPRa, drug repurposing), and supporting research infrastructure (patient registry, AI-powered natural history study, stem cell biobank, and a clinical centers network).

Product overview

The FOXG1 Research Foundation operates as a parent-led, global rare disease organization advancing multiple therapeutic programs for FOXG1 syndrome: FRF-001 AAV9 Gene Replacement Therapy (the lead program entering clinical trials), ASO Therapy, CRISPRa Therapy, RNAi Therapy, tRNA Therapy, and Drug Repurposing initiatives. The organization supports its research through integrated data platforms including the FOXG1 Patient Registry, Stem Cell Biobank (via Coriell), and AI-powered Digital Natural History Study (via Citizen Health). Additional infrastructure includes research assets (mouse models, iPSC lines, brain tissue), a grants program for scientists, clinical centers network, and comprehensive patient/caregiver resources. The therapeutic pipeline addresses different mutation types (loss-of-function, nonsense, missense) to ensure treatments for all FOXG1 patients.

Differentiator

Problem solved

Functional benefit

Products and services

• FRF-001 FOXG1 Gene Replacement Therapy AAV9 viral vector-mediated gene replacement therapy designed to deliver a healthy copy of the FOXG1 gene into cells of individuals with FOXG1 syndrome, replacing the lost FOXG1 protein caused by loss-of-function mutations. Lead therapeutic program for the foundation with FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations.
• FOXG1 ASO Therapy Program Antisense oligonucleotide (ASO) therapeutic program using synthetic molecules designed to bind to FOXG1 mRNA and upregulate FOXG1 gene expression to address loss-of-function mutations.
• FOXG1 CRISPRa Therapy Program CRISPR activation (CRISPRa) therapeutic program that upregulates FOXG1 expression from the endogenous locus without cutting DNA, offering a safer alternative to traditional CRISPR editing for FOXG1 patients.
• FOXG1 RNAi Therapy Program RNA interference (RNAi) therapeutic program using targeted sequences to selectively modulate FOXG1 gene activity, developed in collaboration with the Mallamaci Lab at SISSA, Italy.
• FOXG1 tRNA Therapy Program Suppressor tRNA therapeutic program designed to bypass stop codons caused by nonsense FOXG1 mutations, restoring normal protein synthesis; developed in collaboration with the Ahern Lab (University of Iowa) and the Bedwell Lab (University of Alabama at Birmingham).
• FOXG1 Drug Repurposing Program Screening program for existing small molecule drugs to identify compounds that can treat FOXG1 symptoms including seizures, movement disorders, and cognitive impairment.
• FOXG1 Syndrome Patient Registry Global online registry enabling remote collection of caregiver-reported outcomes and de-identified clinical data from FOXG1 patients worldwide, supporting therapeutic development and trial readiness.
• FOXG1 Stem Cell Biobank Comprehensive biobank containing patient-derived induced pluripotent stem cells (iPSCs) and blood samples from FOXG1 syndrome patients and family members, operated in partnership with the Coriell Institute for Medical Research.
• FOXG1 Digital Natural History Study AI-powered digital platform for longitudinal characterization of clinical, developmental, and behavioral phenotypes in FOXG1 patients, built on the Citizen Health platform and supported by the Chan Zuckerberg Initiative.
• FOXG1 Research Grants and Assets Program Suite of research tools including rolling grants to scientists, mouse models, patient-derived iPSC lines, and postmortem brain tissue access via Autism BrainNet and Harvard Brain Bank for FOXG1 researchers worldwide.
• FOXG1 Patient and Caregiver Resources Comprehensive resource hub providing financial assistance guidance, support groups, therapy resources, travel assistance (e.g., Angel Flight NE partnership), and webinars for families affected by FOXG1 syndrome.
• "Yes, They Can!" Gene Therapy Campaign Fundraising campaign raising $22 million to fund FOXG1 gene replacement therapy clinical trials, featuring peer-to-peer events such as Tom Horton's 500-mile El Camino de Santiago walk.
• FOXG1 Clinical Centers of Excellence Network Network of 11+ leading US clinical centers specializing in Rett syndrome, FOXG1 syndrome, and related developmental and epileptic encephalopathies, partnering with neurologists worldwide for clinical care and research.

Quantifiable outcome

• Patient clinical trials for FOXG1 gene therapy begin 2026 - first-ever treatment for FOXG1 syndrome
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Coriell Institute for Medical ResearchcoreStrategic or Co-development PartnerPartnership to establish a comprehensive Biobank containing patient-derived iPSCs and blood samples from FOXG1 patients and family members. Samples are anonymized and accessible to scientists worldwide to facilitate expanded research and therapeutic development.
• Autism BrainNet (Simons Foundation)coreStrategic or Co-development PartnerPartnership for FOXG1 Syndrome Postmortem Brain Tissue Bank. Brain donation program with 24-hour window for collection. Centers in USA, Canada, and UK. No cost to families. Applications evaluated for scientific merit.
• IQVIA BiotechcoreImplementation/ SI/ Consulting PartnerClinical trial vendor partnership to support the FRF-001 gene therapy clinical trial execution and data integrity for the upcoming multi-site, international clinical trial.
• Citizen HealthcoreStrategic or Co-development PartnerDigital Natural History Study powered by Citizen Health AI platform. Enables longitudinal characterization of clinical, developmental, and behavioral phenotypes in FOXG1 patients. Foundation's approach is now being used by 100+ other rare disease groups.
• University at Buffalo - FOXG1 Research Center (Lee Lab)coreStrategic or Co-development PartnerFOXG1 Research Center at University at Buffalo led by Soo-Kyung Lee and Jae W. Lee, two leading neuroscientists studying FOXG1 syndrome and parents of a teenager with FOXG1 syndrome. Published groundbreaking research supporting gene therapy program.
• Mallamaci Lab (SISSA, Italy)coreStrategic or Co-development PartnerResearch collaboration for FOXG1 RNAi Therapy. Lab at Laboratory of Cerebral Cortex Development - SISSA, Italy is working on RNAi sequences to upregulate and downregulate FOXG1 gene expression.
• Ahern Lab (University of Iowa)coreStrategic or Co-development PartnerResearch collaboration for FOXG1 tRNA Therapy exploring suppressor tRNA technology to correct nonsense mutations by bypassing stop codons.
• Bedwell Lab (University of Alabama at Birmingham)coreStrategic or Co-development PartnerResearch collaboration for FOXG1 tRNA Therapy focused on tRNA technology platform for nonsense mutation correction.
• Fink Lab (University of California, Davis)coreStrategic or Co-development PartnerResearch collaboration for FOXG1 CRISPRa Therapy. Working on CRISPRa sequences that upregulate expression from endogenous FOXG1 locus, tested in human stem cells.
• Texas Children's HospitalcoreStrategic or Co-development PartnerFOXG1 Clinical Center of Excellence. Partnership with neurologists and specialists to help inform the standard of care for FOXG1 patients and as key opinion leaders on various studies.
• Boston Children's HospitalcoreStrategic or Co-development PartnerFOXG1 Clinical Center of Excellence. Collaboration with leading pediatric neurology specialists for clinical care and research.
• NYU Langone HealthcoreStrategic or Co-development PartnerFOXG1 Clinical Center of Excellence. Comprehensive Epilepsy Center partnership for FOXG1 syndrome care and research.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerFOXG1 Clinical Center of Excellence. Partnership for Rett Spectrum Clinic and neurogenetics research.
• Angel Flight NEminorStrategic or Co-development PartnerFree air and ground transportation for rare disease patients seeking medical care. Helps FOXG1 families access specialized care at clinical centers.
• Blockchain.comminorGTM or Marketing PartnerCorporate sponsor of the 'Yes, They Can!' campaign supporting FOXG1 gene therapy development.
• CombinedBrainminorStrategic or Co-development PartnerRare disease partner collaboration to drive progress on ICD-10 code and other advocacy initiatives.
• Billy FootwearminorGTM or Marketing PartnerAffiliate partnership where Billy donates 15% of purchases to the foundation through referral link.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cure SMA: Parent-led rare disease foundation that funded and drove development of Spinraza, the first approved treatment for spinal muscular atrophy. Directly comparable as a disease-specific nonprofit that independently advanced a therapeutic from bench to FDA approval, including registry, clinical network, and capital-raising infrastructure for an ultra-rare pediatric neurologic disorder.
• Parent Project Muscular Dystrophy (PPMD): Parent-led nonprofit focused on Duchenne muscular dystrophy that pioneered the patient-driven drug development model, including gene therapy programs (Sarepta) and multi-modal pipelines. Closely matches FOXG1's playbook of community fundraising, research grants, and direct advocacy to bring first-in-class treatments to ultra-rare pediatric populations.
• Rett Syndrome Research Trust: Parent-driven organization accelerating cures for Rett syndrome, a related neurodevelopmental disorder sharing DEE (Developmental and Epileptic Encephalopathy) clinical space with FOXG1. Highly comparable in mission, patient population characteristics, AAV gene therapy strategy, and clinical trial infrastructure investments.
• CHDI Foundation: Large private foundation that funds and manages drug development for Huntington's disease, another monogenic neurologic disorder. Directly comparable model of a disease-focused nonprofit running an in-house pipeline of gene-targeting therapeutics, biomarker research, and clinical trials without traditional pharma ownership.
• CureDuchenne: Disease-specific nonprofit funding exon-skipping and gene therapy development for Duchenne muscular dystrophy. Comparable as a parent-led foundation executing capital campaigns for clinical-stage genetic medicines and operating biobanks/registries for trial recruitment.

Broad incumbents

• Cystic Fibrosis Foundation: The gold-standard patient-led rare disease foundation that funded development of Trikafta/Kalydeco and pioneered the venture philanthropy model. Demonstrates the upper-bound outcome for an organization like FOXG1, including multi-billion-dollar royalty monetization that funded further pipeline investment.
• National Organization for Rare Disorders (NORD): Umbrella advocacy organization representing ~300 rare disease patient groups including FOXG1 Research Foundation (member since 2025). Comparable as a coordinating body driving policy, ICD coding, and legislative advocacy (e.g., Rare Disease Act) that benefits the rare disease ecosystem including FOXG1.
• Global Genes: Leading rare disease advocacy and patient organization partner, formally partnered with FOXG1 Research Foundation. Operates broader RARE Patient Organization Partner program; comparable as ecosystem-level platform serving multiple rare disease foundations with education, tooling, and corporate partnership channels.
• EveryLife Foundation for Rare Diseases: Public policy advocacy organization for the rare disease community. Comparable as a peer nonprofit influencing legislative and regulatory frameworks (FDA, NIH, CMS) that shape FOXG1's clinical and reimbursement pathways; partner in CombinedBrain collaboration.

Emerging players

• Batten Disease Support and Research Association (BDSRA): Patient organization advancing gene therapies (AAV-based) for CLN3/Batten disease, another ultra-rare pediatric neurologic disorder. Comparable in mission, ultra-rare patient scale, gene therapy modality, and parent-led fundraising strategy targeting similar FDA designations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Foxg1Research
• Facebookfacebook.com/foxg1research
• LinkedInlinkedin.com/company/foxg1research
• Instagraminstagram.com/foxg1research

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FOXG1 Research Foundation